Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML.
10.7534/j.issn.1009-2137.2014.05.034
- Author:
Zhi GUO
1
;
Hui-Ren CHEN
2
;
Xiao-Dong LIU
1
;
Jing-Xing LOU
1
;
Kai YANG
1
;
Yuan ZHANG
1
;
Peng CHEN
1
;
Xue-Peng HE
1
Author Information
1. Department of Hematology, General Hospital of Beijing Military Command, Beijing 100700, China.
2. Department of Hematology, General Hospital of Beijing Military Command, Beijing 100700, China. E-mail: chenhui-ren@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Allografts;
Cytarabine;
Disease-Free Survival;
Erythropoietin;
analysis;
Female;
Granulocyte Colony-Stimulating Factor;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
therapy;
Male;
Middle Aged;
Transplantation Conditioning;
Vidarabine;
analogs & derivatives;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(5):1359-1364
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the effect and feasibility of reduced conditioning intensity allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed ETO positive acute myeloid leukemia (AML) patients. Fifteen cases of relapsed AML received the reducing conditioning intensity allo-HSCT from January 2011 to January 2013 in Beijing Military Command General Hospital. All patients were high-risk type of relapsed or refractory AML, including 10 males and 5 females, aged from 16 to 48 years old with mean age of 32.5 years. Ten cases are HLA-identical matching and other 5 cases are HLA-haploidentical.donors received granulocyte colony-stimulating factor (G-CSF) to mobilize the peripheral blood stem cell for transplantation. Conditioning regimen was fludarabine combined with busulfex, cytarabine and cyclophosphamide. The preventive donor's peripheral blood stem cell infusion were performed after 3 months of transplantation, and the toxicity, GVHD and disease-free survival were observed in patients after transplantation. The results showed that all patients achieved hematopoietic reconstitution, the average time of neutrophils ≥ 0.5 × 10⁹/L and platelets ≥ 20 × 10⁹/L were 15.5 d and 16.8 d respectively. Implantation was confirmed by the evidence of 100% donor hematopoiesis. Follow-up to June 2014, with a median follow-up duration of 27.5 months (18-54 months), GVHD occurred in 8 cases of all patients, one died of complication, the other 4 cases died of relapse and the other three patients remained in disease-free survival. The disease-free survival rate of 2-year was 66.7%,the longest disease-free survival time was up to 54 months. It is concluded that the reduced conditioning intensity allo-HSCT is the effective and safe method for relapsed AML with ETO-positive, and it may be chosen as a treatment method for relapsed ETO positive AML patients.
